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Assessing the degree to which chronic GVHD (cGVHD) may
limit range of joint motion (ROM) needs to be accomplished re-
liably, simply, and in a clinically meaningful way. We evaluated
NIH recommended scales and a photographic ROM (P-ROM)
scale [Carpenter PA, Blood 2011] for their correlation with pro-
vider (MD) and patient (PT) perceptions of joint change.
Patients andMethods:As part of a multicenter, prospective, lon-
gitudinal observational cohort, 458 patients receiving systemic
cGVHD therapy were studied; 177/327 (54%) with baseline
P-ROM had limited ROM defined by any 1-6 P-ROM score
(7 5 full ROM) at the wrists, elbows, shoulders or, 1-3 score
(4 5 full) at the ankles. NIH cGVHD joint scoring was categor-
ical: 0 5 full ROM (or not limited by cGVHD) and scores 1 to
3 were based upon MD opinion of PT extremity tightness, de-
gree of reduction in both ROM and activities of daily living.
At follow-up visits, as anchors, PT and MD rated separately their
perception of change in joint cGVHD. Multivariable models
were used to measure associations between MD/PT perceived
changes (improved, stable, worse) and changes in P-ROM mea-
sures, NIH joint scores, and other items in the 2005 NIH con-
sensus recommendations.
Results:ROM limitation was common (see Table). It was seen in
patients with a longer duration of cGVHD, and was associated
(p\0.01) with NIH skin response measures, the NIH 0-3 joint
score, Lee energy subscale but not the Human Activity Profile,
2-minute walk test or grip strength. Compared to previous visits
with ROM limitation (N 5 369 visits), both MDs (60%) and
PTs (47%) were more likely to report perceived improvement
than worsening (4% MD, 9% PT). In multivariable analyses,
MD perceptions of change in joint cGVHD were best predicted
by P-ROM wrist score (p 5 0.003), NIH 0-3 joint score
(p\0.001) and SF36 bodily pain subscale (p 5 0.01). PT per-
ceptions of changes in joint cGVHD were predicted by SF36
bodily pain score (p 5 0.01). Changes in the extrapolated
Rodnan skin score and the NIH 0-3 skin score were not asso-
ciated with perceived changes in joint cGVHD by MD and PT.
Conclusions: Joint involvement is common and should be assessed
in all patients with cGVHD. The NIH joint score (1 item), P-ROM
scale (4 items) and the SF36 bodily pain subscale (2 items) appeared
to have the most clinical utility for measuring symptom change.
Finer gradations within the P-ROM’s clinically relevant range
(scores 4-7) may improve its sensitivity to change.Table. Analysis of Categorical and Continuous Variables as-
sociated with ROM
ROM notMeasuresROM involved
(N 5 177)involved
(N 5 150) P valueWrist P-ROM Score (‘‘Prayer position’’)(%)7 (full) 40 1006 40 05 11 04 3 03 1 02 3 01 2 0Total involved 60 0 NA*(Continued )Table. (Continued)MeasuresROM involved
(N 5 177)ROM not
involved
(N 5 150) P valueShoulder Abduction P-ROM Score (%)7 (full) 57 1006 27 05 12 04 2 03 1 02 0 01 1 0Total involved 43 0 NA*Elbow Extension P-ROM Score (%)7 (full) 69 1006 20 05 8 04 2 03 0 02 1 01 0 0Total involved 31 0 NA*Ankle Dorsiflexion P-ROM Score4 (full) 39 1003 54 02 7 01 0 0Total involved 61 0 NA*NIH Skin Response Measures (%BSA),
Mean (SD)Erythema 5.0 (15.6) 9.7 (20.1) .009Moveable sclerosis 4.6 (10.3) 0.8 (4.2) <.0001Non-moveable sclerosis 3.1 (8.8) 0.0 (0.0) <.0001Lee Energy Score, Median (range) 35.7 (0.0-100) 25.0 (0.0-75.0) .002*Comparisons for these measures are not meaningful because they are
used to define joint involvement. Abbreviations: ROM, range of motion;
BSA, body surface area415
INTERRUPTION OF THE IFNgR/CXCR3 AXIS RESULTS IN ALTERED T CELL
TRAFFICKING IN VIVO AND ABROGATION OF GVHD WHILE MAINTAIN-
ING A ROBUST GVL RESPONSE
Choi, J., Ziga, E.D., Ritchey, J., Collins, L., Prior, J., Piwnica-
Worms, D., DiPersio, J.F. Washington University School of Medicine
The goal of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is to minimize graft-versus-host disease (GvHD) while
maintaining a beneficial graft-versus-leukemia (GvL) effect. This
can be achieved by infusing regulatory T cells (Tregs) which sup-
press GvHD but have only limited effects on GvL. Unfortunately,
Tregs exist in low frequency in the peripheral blood, are costly to pu-
rify and expand, and after expansion are difficult to isolate due to the
lack of cell surfacemarkers. Thus, alternative therapeutic approaches
are needed.
Using an MHC-mismatched GvHDmodel, B6 (H-2b)/ Balb/c
(H-2d), we demonstrated that infusion of IFNgR deficient
(IFNgR-/-) allogeneic donor T cells induced significantly less
GvHD, compared to WT T cells, as determined by survival (74%
vs. 0%; p 5 0.0004), weight loss and percentages of B220+ B cells
(12.4% vs. 3.8%; p 5 0.0205), CD3+ T cells (14.3% vs. 4.3%; p 5
0.0025) in blood. Of note was that the IFNgR-/- donor T cells in-
duced a robust GvL effect in both systemic leukemia and solid tumor
models using luciferase-expressing A20 cells derived from Balb/c.
We found that IFNgR-/- T cells responded normally to allogeneic
antigens in vitro, based on mixed lymphocyte reactions, and ex-
pressed similar levels of granzyme B, compared to WT T cells. Us-
ing bioluminescence imaging (BLI) and luciferase-transduced WT
and IFNgR-/- T cells, we observed that IFNgR-/- T cells trafficked
primarily to the spleen while WT T cells trafficked to gastrointesti-
nal tract and lymph nodes, which are major GvHD target organs.S357
S358 Poster Session IIThese findings suggest that the reduced GvHD was not due to re-
duced function, altered subsets or relative deficiency of allogeneic
donor T cells but from an alteration of in vivo trafficking of
IFNgR-/- T cells compared to WT T cells. We further demon-
strated that the IFNgR-mediated signaling in alloreactive donor T
cells was required for expression of CXCR3 which has been impli-
cated in trafficking of T cells to areas of inflammation and target or-
gans, commonly known to be the sites of GvHD. In addition,
overexpression of CXCR3 in IFNgR-/- T cells rescued the
GvHD-inducing function of IFNgR-/- T cells. CXCR3-/- T cells
and pharmacological approaches using inhibitors of IFNgR signal-
ing recapitulated the anti-GvHD (and pro-GvL) effects seen in
IFNgR-/- T cells after allo-HSCT. Thus, the IFNgR-CXCR3
axis represents a promising therapeutic target for future efforts to
mitigate GvHD while maintaining GvL after allo-HSCT.
416
ULTRA LOW-DOSE IL-2 MEDIATED EXPANSION OF REGULATORY T
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CD4+ CD25+ FoxP3+ regulatory T cells (Tregs) may prevent graft-
versus-host disease (GvHD) after allogeneic hematopoietic stem cell
transplantation (HSCT). We and others have previously used low-
dose IL-2 therapy in HSCT recipients in an attempt to enhance an-
titumor immunity and observed low rates of GvHD. Retrospective
analysis showed that patients who received IL-2 had higher levels
of FoxP3+ T cells than controls, suggesting that IL-2 may preferen-
tially expand Tregs in vivo, thereby preventing GvHD.We therefore
initiated a prospective phase II clinical trial to evaluate the efficacy
and toxicity of ultra low-dose (ULD) IL-2 injections following allo-
geneic HSCT to promote Treg expansion in vivo and prevent signif-
icant GvHD. As our control population, we evaluated Treg
reconstitution post HSCT in patients who did not receive IL-2.
Twelve patients have been treated with ULD IL-2 (100,000 to
200,000 IU/m2 3x weekly SC) post HSCT starting before day 30
and continuing for 6 to 12 weeks. Median age at time of HSCT
was 14 years (range, 6y to 56y). Eight patients received matched sib-
ling donor transplants and four received alternative donor trans-
plants with Campath 1-H for in vivo T-cell depletion. By flow
cytometry, all patients demonstrated a rise in the percentage of
CD4+ CD25+ FoxP3+ Tregs by 6 weeks following initiation of IL-2
therapy with a mean of 5.2% (range, 0 to 11.0%) pre IL-2 to
a mean of 13.2% (range, 4.4 to 31.1%) post treatment. Compared
to the control HSCT population, a significant rise in Treg percent-
ages was found at 1 and 3 months post HSCT in patients receiving
IL-2 (1 month: 12.8% vs. 6.8%, p 5 0.008; 3 months: 10.5% vs.
6.2%, p5 0.02). Functional analyses of CD4+ CD25bright cells dem-
onstrated suppression ofmixed lymphocyte reactions. There were no
grade 3 or 4 toxicities associated with ULD IL-2. No patients on
study developed grade III-IV acute GvHD, compared to 4/31
(13%) of controls. IL-2 recipients also retained T cells reactive to vi-
ral and tumor antigens, and only 25%of study patients versus 61%of
the control group developed viral infections. Hence, ULD IL-2 is
well-tolerated, expands a CD4+ CD25+ FoxP3+ Treg population in
vivo, andmay be associated with a lower incidence ofGvHDand viral
infections; the study continues to evaluate these putative benefits.417
INTERLEUKIN-15 (IL-15) ADMINISTRATION INCREASES GRAFT VERSUS
LEUKEMIA ACTIVITY IN RECIPIENTS OF HAPLOIDENTICAL HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
Sauter, C., Bailey, C., Biswas, C., Budak, T., Panis, M., Alpdogan, O.
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
The success of haploidentical (HI) hematopoietic stem cell trans-
plantation (HSCT), suggests that graft-versus leukemia (GVL) ef-
fect might have a substantial role in this transplant modality.Rigorous T-cell depletion (TCD) of the graft decreases the occur-
rence of graft-versus-host disease (GVHD) in HI-HSCT, however
this results in immunodeficiency and high disease relapse rate, espe-
cially in patients with resistant or residual leukemia. Therefore, en-
hancingGVL activity of HSCTwithout increasingGVHD is crucial
for improving the outcome of haploidentical transplant.
Post-transplant IL-15 administration is shown to enhance im-
mune reconstitution, particularly donor-derived NK and CD8+ T
cell populations in murine models. We evaluated the efficacy of
IL-15 for enhancing GVL effect in recipients of HI-HSCT. For de-
veloping clinically relevant haploidentical transplant models, differ-
ent hybrid mice with B6 background that share the same haplotype
(H2Kb) are used for our murine haploindentical transplant experi-
ments. Lethally irradiated B6D2F1/J (H2Kb/d) mice are trans-
planted with B6CBAF1/J (H2Kb/k) TCD bone marrow (BM) and
T cells at varying doses. Some animals were also given P815 tumor
cells on the day of transplant. Administration of IL-15 significantly
increased the numbers of CD8+ T and NK cells in the spleen and
BM in the T cell depleted model at post-transplant day 28. Infusion
of very low dose haploidentical T cells (1x104) with TCD-BM re-
sulted in a conflicting effect on immune reconstitution, i.e. increased
T cell numbers, and decreased NK cell population. Post-transplant
IL-15 administration also changed this immune reconstitution pat-
tern and significantly increased both T and NK cell numbers in re-
cipients of HI-HSCT. In P815 challenged mice that were
transplanted with very low dose T cell added TCD-BM, IL-15 ad-
ministration significantly increased anti-tumor activity of the graft
and improved survival without increasing GVHD. This effect was
observed when IL-15 administration was given at a later time point
rather than immediately following transplantation, possibly allowing
for more donor cell engraftment and T cell proliferation to take
place. IL-15 administration without T cell infusion did not result
in any survival improvement. We conclude that in our experimental
HI transplant models, IL-15 administration augments anti-tumor
activity of the HI-HSCT without increasing GVHD risk, and this
effect requires presence of donor derived T cells.418
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Background: morbidity and mortality resulting from acute and
chronicGVHD remains themost serious challenge to wider applica-
bility of T-cell replete allogeneic HCT for otherwise incurable he-
matologic diseases. Developing effective regimens acute GVHD
(aGVHD) prophylaxis is of vital importance due to lack of effective
treatments, mainly when refractory to corticosteroids. Conflicting re-
sults have been observed when comparing, directly or indirectly,
MMF-based against MTX-based regimens for aGVHD prophylaxis.
Methods: a systematic and comprehensive literature search was per-
formed using MEDLINE databases from 1966 to 07/31/2011. All
completed prospective-randomized (phase II or III) clinical trials
(RCT) or retrospective non-randomized comparisons (NRC) pub-
lished as a full manuscript were eligible for inclusion, but data pub-
lished only in abstract form was not. Outcomes extracted from
selected studies (RCT 5 2, retrospective NRC 5 2) included:
time-to-ANC engraftment, time-to-platelets engraftment, inci-
dences of grade II-IV aGVHD and chronic GVHD (cGVHD), inci-
dence of severe mucositis, frequency of pain control requirement,
frequency of total parenteral nutrition (TPN) use, relapse rate, inci-
dence of non-relapse mortality (NRM) and overall survival (OS).
Results: pooled analysis shows that use of MMF, for aGVHD pro-
phylaxis, results in significantly faster platelets engraftment (pooled
hazard ratio (HR)5 1.15 (95%CI, 1.08,1.23; p\0.0001)), a lower in-
cidence of severe mucositis (pooled risk ratio (RR) 5 0.48 (95%CI,
0.32, 0.71; p 5 0.0003)), and less use of TPN (pooled RR 5 0.52
(95%CI, 0.34, 0.80; p5 0.003)) or narcotics for pain control (pooled
risk ratio5 0.76 (95%CI, 0.63, 0.91; p5 0.002)) compared toMTX.
